Pompe disease diagnosis and management guideline ACMG Work Group on Management of Pompe Disease :

ACMG Work Group on Management of Pompe Disease: Priya S. Kishnani, MD, Robert D. Steiner, MD (Chair), Deeksha Bali, PhD, Kenneth Berger, MD, Barry J. Byrne, MD, PhD, Laura Case, PT, DPT, John F. Crowley, JD, MBA, Steven Downs, MD, R. Rodney Howell, MD, Richard M. Kravitz, MD, Joanne Mackey, CPNA, Deborah Marsden, MBBS, Anna Maria Martins, MD, David S. Millington, PhD, Marc Nicolino, MD, PhD, Gwen O’Grady, MA, Marc C. Patterson, MD, FRACP, David M. Rapoport, MD, Alfred Slonim, MD, Carolyn T. Spencer, MD, Cynthia J. Tifft, MD, PhD, and Michael S. Watson, PhD

[1]  P. Odenrick,et al.  Isometric muscle force and anthropometric values in normal children aged between 3.5 and 15 years. , 2020, Scandinavian journal of rehabilitation medicine.

[2]  P. Meikle,et al.  Newborn screening for lysosomal storage disorders. , 2006, Molecular genetics and metabolism.

[3]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[4]  Barry Byrne,et al.  Diagnostic challenges for Pompe disease: An under-recognized cause of floppy baby syndrome , 2006, Genetics in Medicine.

[5]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[6]  Amanda L. Cook,et al.  Ambulatory electrocardiogram analysis in infants treated with recombinant human acid α-glucosidase enzyme replacement therapy for Pompe disease , 2006, Genetics in Medicine.

[7]  S. Idriss,et al.  Electrocardiographic response to enzyme replacement therapy for Pompe disease , 2006, Genetics in Medicine.

[8]  P. Kishnani,et al.  Physical therapy management of Pompe disease , 2006, Genetics in Medicine.

[9]  S. Dimauro,et al.  Benign course of glycogen storage disease type IIb in two brothers: Nature or nurture? , 2006, Muscle & nerve.

[10]  D. Koeberl,et al.  Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  B. Byrne,et al.  Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors , 2005, Gene Therapy.

[12]  Yuan-Tsong Chen,et al.  Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. , 2005, Molecular genetics and metabolism.

[13]  D. Koeberl,et al.  Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  M. Littner,et al.  Practice parameters for the indications for polysomnography and related procedures: an update for 2005. , 2005, Sleep.

[15]  B. Byrne,et al.  Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. , 2005, Human gene therapy.

[16]  D. Marsden Infantile onset Pompe disease: A report of physician narratives from an epidemiologic study , 2005, Genetics in Medicine.

[17]  B. Wong,et al.  Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004 , 2005, Neuromuscular Disorders.

[18]  T. Voit,et al.  Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.

[19]  K. Bushby,et al.  Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention , 2005, Neuromuscular Disorders.

[20]  A. Janssens,et al.  Late-onset Pompe disease primarily affects quality of life in physical health domains , 2004, Neurology.

[21]  M. Gelb,et al.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. , 2004, Clinical chemistry.

[22]  N. Chamoles,et al.  Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[23]  David Gozal,et al.  Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. , 2004, American journal of respiratory and critical care medicine.

[24]  C. I. Zeeuw,et al.  Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse , 2004, Neurobiology of Disease.

[25]  A. Ross,et al.  Anaesthetic management of infants with glycogen storage disease type II: a physiological approach , 2004, Paediatric anaesthesia.

[26]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[27]  C. Rubin,et al.  Low Magnitude Mechanical Loading Is Osteogenic in Children With Disabling Conditions , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  D. V. Leenen,et al.  Twenty‐two novel mutations in the lysosomal α‐glucosidase gene (GAA) underscore the genotype–phenotype correlation in glycogen storage disease type II , 2004, Human mutation.

[29]  W. Flemons,et al.  Comparison of home oximetry monitoring with laboratory polysomnography in children. , 2003, Chest.

[30]  B. Bembi,et al.  Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II , 2003, Journal of Inherited Metabolic Disease.

[31]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[32]  Ferhaan Ahmad,et al.  Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy , 2003, Circulation.

[33]  L. Severijnen,et al.  Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy , 2003, Muscle & nerve.

[34]  Yuan-Tsong Chen,et al.  Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. , 2003, Analytical biochemistry.

[35]  I. McEwen,et al.  Use of power mobility for a young child with spinal muscular atrophy. , 2003, Physical therapy.

[36]  A. Simonds,et al.  Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness , 2003, European Respiratory Journal.

[37]  S. Haley,et al.  Development of a disease-specific disability instrument for Pompe disease , 2003, Pediatric rehabilitation.

[38]  M. Eagle Report on the Muscular Dystrophy Campaign workshop: Exercise in neuromuscular diseases Newcastle, January 2002 , 2002, Neuromuscular Disorders.

[39]  A. Garwick,et al.  Family-centered care coordination for children with special needs across multiple settings. , 2002, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[40]  W. Fowler Consensus Conference Summary: Role of Physical Activity and Exercise Training in Neuromuscular Diseases , 2002, American journal of physical medicine & rehabilitation.

[41]  O. Bodamer,et al.  L-alanine supplementation in late infantile glycogen storage disease type II. , 2002, Pediatric neurology.

[42]  B. Byrne,et al.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  M. Mccaffery Choosing a faces pain scale. , 2002, Nursing.

[44]  Yuan-Tsong Chen,et al.  Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  B. Byrne,et al.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). , 2002, Current molecular medicine.

[46]  P. Laforêt,et al.  Juvenile and adult-onset acid maltase deficiency in France: Genotype–phenotype correlation , 2001, Neurology.

[47]  T. Voit,et al.  Sleep-disordered breathing and respiratory failure in acid maltase deficiency , 2001, Neurology.

[48]  P. Meikle,et al.  Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. , 2001, Clinical chemistry.

[49]  C. L. Hicks,et al.  The Faces Pain Scale – Revised: toward a common metric in pediatric pain measurement , 2001, Pain.

[50]  D. Millington,et al.  Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. , 2000, Analytical biochemistry.

[51]  C. Oktenli Renal Magnesium Wasting, Hypomagnesemic Hypocalcemia, Hypocalciuria and Osteopenia in a Patient with Glycogenosis Type II , 2000, American Journal of Nephrology.

[52]  O. Bodamer,et al.  The effects of l-alanine supplementation in late-onset glycogen storage disease type II , 2000, Neurology.

[53]  F. Martiniuk,et al.  Identification of two subtypes of infantile acid maltase deficiency. , 2000, The Journal of pediatrics.

[54]  U. Werlauff,et al.  A randomized comparative study of two methods for controlling Tendo Achilles contracture in Duchenne muscular dystrophy , 2000, Neuromuscular Disorders.

[55]  K. Waters,et al.  Nocturnal Pulse Oximetry as an Abbreviated Testing Modality for Pediatric Obstructive Sleep Apnea , 2000 .

[56]  M. Kroos,et al.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling , 1999, European Journal of Human Genetics.

[57]  N. Raben,et al.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Metzl,et al.  An Interesting Case of Infant Sudden Death: Severe Hypertrophic Cardiomyopathy in Pompe's Disease , 1999, Pacing and clinical electrophysiology : PACE.

[59]  A. Reuser,et al.  A diagnostic protocol for adult-onset glycogen storage disease type II , 1999, Neurology.

[60]  J. Varni,et al.  The PedsQL: measurement model for the pediatric quality of life inventory. , 1999, Medical care.

[61]  R. Hirschhorn,et al.  Frequency of mutations for glycogen storage disease type II in different populations: the Δ525T and Δexon 18 mutations are not generally “common” in white populations , 1999, Journal of medical genetics.

[62]  J E Ware,et al.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.

[63]  W. Rom,et al.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. , 1998, American journal of medical genetics.

[64]  D. Pauly,et al.  Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle , 1998, Gene Therapy.

[65]  C. McDonald,et al.  Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. , 1998, Physical medicine and rehabilitation clinics of North America.

[66]  C. Granger,et al.  Interrater agreement and stability of the Functional Independence Measure for Children (WeeFIM): use in children with developmental disabilities. , 1997, Archives of physical medicine and rehabilitation.

[67]  J. Yewdell,et al.  Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. , 1997, Human gene therapy.

[68]  O. Bodamer,et al.  Dietary treatment in late-onset acid maltase deficiency , 1997, European Journal of Pediatrics.

[69]  R. Brady,et al.  High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Reuser,et al.  Prenatal Diagnosis of Glycogen Storage Disease Type II: Enzyme Assay or Mutation Analysis? , 1995, Pediatric Research.

[71]  S. Krechel,et al.  CRIES: a new neonatal postoperative pain measurement score. Initial testing of validity and reliability , 1995, Paediatric anaesthesia.

[72]  A. Reuser,et al.  Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. , 1994, Biochemical and biophysical research communications.

[73]  S. Pandya,et al.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. , 1994, Physical therapy.

[74]  M. Margolis,et al.  Obstructive sleep apnea syndrome in acid maltase deficiency. , 1994, Chest.

[75]  Larry H. Ludlow,et al.  Pediatric Evaluation of Disability Inventory , 1994 .

[76]  R. Manfredi,et al.  Elevation of transaminases as an early sign of late-onset glycogenosis type II , 1993, European Journal of Pediatrics.

[77]  J. Chi,et al.  A case of juvenile form Pompe's disease manifested as chronic alveolar hypoventilation. , 1993, Journal of Korean medical science.

[78]  T. Young,et al.  The occurrence of sleep-disordered breathing among middle-aged adults. , 1993, The New England journal of medicine.

[79]  Yuan-Tsong Chen,et al.  Prenatal diagnosis of Pompe's disease (type ii glycogenosis) in chorionic villus biopsy using maltose as a substrate , 1992, Prenatal diagnosis.

[80]  James W. Hall Handbook of Auditory Evoked Responses , 1991 .

[81]  T. Choudhury,et al.  Glycogen storage disease (type-III). , 1991, Indian pediatrics.

[82]  B. Riou,et al.  Effects of Etomidate on the Cardiac Papillary Muscle of Normal Hamsters and Those with Cardiomyopathy , 1990, Anesthesiology.

[83]  R. Reeve,et al.  The faces pain scale for the self-assessment of the severity of pain experienced by children: Development, initial validation, and preliminary investigation for ratio scale properties , 1990, Pain.

[84]  M. Hirayama,et al.  Late-onset acid maltase deficiency associated with intracranial aneurysm , 1988, Journal of Neurology.

[85]  C Tabary,et al.  FOR HOW LONG MUST THE SOLEUS MUSCLE BE STRETCHED EACH DAY TO PREVENT CONTRACTURE? , 1988, Developmental medicine and child neurology.

[86]  M. Hart,et al.  Alpha‐glucosidase deficiency and basilar artery aneurysm: Report of a sibship , 1987, Annals of neurology.

[87]  N. Soni,et al.  Pompe's disease and anaesthesia , 1986, Anaesthesia.

[88]  V. Mathiowetz,et al.  Grip and pinch strength: norms for 6- to 19-year-olds. , 1986, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[89]  A. Pearson,et al.  Bone marrow transplantation for glycogen storage disease type II (Pompé's disease) , 1986, The New England journal of medicine.

[90]  L. Poenaru,et al.  Prenatal diagnosis of glycogenosis type II (Pompe's disease) using chorionic villi biopsy , 1985, Clinical genetics.

[91]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[92]  V. Mathiowetz,et al.  Grip and pinch strength: normative data for adults. , 1985, Archives of physical medicine and rehabilitation.

[93]  E. Joosten,et al.  Respiratory failure as initial symptom of acid maltase deficiency. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[94]  Paul J. Vignos,et al.  Physical models of rehabilitation in neuromuscular disease , 1983, Muscle & nerve.

[95]  K. Hirschhorn,et al.  Improvement of muscle function in acid maltase deficiency by high‐protein therapy , 1983, Neurology.

[96]  Fowler Wm Rehabilitation management of muscular dystrophy and related disorders: II. Comprehensive care. , 1982 .

[97]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[98]  F. Ellis Inherited muscle disease. , 1980, British journal of anaesthesia.

[99]  G. Hutchins,et al.  Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. , 1978, American heart journal.

[100]  P. Gillette,et al.  Electrophysiological mechanism of the short PR interval in Pompe disease. , 1974, American journal of diseases of children.

[101]  W. Schubert,et al.  Treatment related observations in solid tissues, fibroblast cultured and amniotic fluid cells of type II glycogenosis, Hurler disease and metachromatic leukodystrophy. , 1973, Birth defects original article series.

[102]  A. Engel,et al.  The spectrum and diagnosis of acid maltase deficiency , 1973, Neurology.

[103]  P. Vignos,et al.  Management of progressive muscular dystrophy in childhood. , 1963, JAMA.

[104]  J. Horner,et al.  Swallowing in torticollis before and after rhizotomy , 2006, Dysphagia.

[105]  D. Pongratz,et al.  Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype. , 2005, Neurology.

[106]  K. Nagashima,et al.  Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  D. Koeberl,et al.  Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  C. Angelini,et al.  Adult acid maltase deficiency: an open trial with albuterol and branched- chain aminoacids , 2004 .

[109]  Ellen B. Roecker,et al.  A penetration-aspiration scale , 2004, Dysphagia.

[110]  W. Hop,et al.  Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. , 2004, Pediatrics.

[111]  Gary C. Sieck,et al.  ATS/ERS Statement on respiratory muscle testing. , 2002, American journal of respiratory and critical care medicine.

[112]  A. Orlacchio,et al.  Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. , 2002, Human molecular genetics.

[113]  J. Smeitink,et al.  Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. , 2001, Journal of inherited metabolic disease.

[114]  J. Charrow,et al.  Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.

[115]  A. Reuser,et al.  Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. , 2000, Lancet.

[116]  P. L. Smith,et al.  Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment. , 2000, American journal of respiratory and critical care medicine.

[117]  R W Bohannon,et al.  Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. , 1997, Archives of physical medicine and rehabilitation.

[118]  T. Bertorini,et al.  Respiratory insufficiency in adult-type acid maltase deficiency. , 1993, Southern medical journal.

[119]  C. Granger,et al.  The functional independence measure: a new tool for rehabilitation. , 1987, Advances in clinical rehabilitation.

[120]  W. Braunsdorf Fusiform aneurysm of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe's disease). , 1987, Neurosurgery.

[121]  H. Meinck,et al.  [Hemodynamic findings in the adult form of type II glycogenosis]. , 1986, Zeitschrift für Kardiologie.

[122]  J. L. Griffin Infantile acid maltase deficiency , 1984, Virchows Archiv. B, Cell pathology including molecular pathology.

[123]  L. Poenaru,et al.  White blood cells and the diagnosis of alpha-glucosidase deficiency. , 1980, Pediatric research.

[124]  D. A. Gibson,et al.  Pseudohypertrophic muscular dystrophy and its surgical management: review of 30 patients. , 1970, Canadian journal of surgery. Journal canadien de chirurgie.

[125]  H. Hers α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease) , 1963 .

[126]  P. Vignos,et al.  A study of contractures in muscular dystrophy. , 1959, Archives of physical medicine and rehabilitation.